Juan Casanova-Sandoval, Gema Miñana-Escrivà, Eduard Bosch-Peligero, Juan Francisco Muñoz-Camacho, Diego Fernández-Rodríguez, Kristian Rivera, Agustín Fernández-Cisnal, Daniel Valcárcel-Paz, Marcos García-Guimarães
{"title":"[[The ultrathin-strut everolimus-eluting stent in a real-world population: the Everythin multicenter registry]].","authors":"Juan Casanova-Sandoval, Gema Miñana-Escrivà, Eduard Bosch-Peligero, Juan Francisco Muñoz-Camacho, Diego Fernández-Rodríguez, Kristian Rivera, Agustín Fernández-Cisnal, Daniel Valcárcel-Paz, Marcos García-Guimarães","doi":"10.24875/RECIC.M24000484","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Ultrathin-strut stents (UTS) represent a significant advancement in percutaneous coronary intervention. This study aimed to evaluate the safety and short- to mid-term outcomes of stenting with the thinnest struts on the market (50 µm) using a biodegradable everolimus-eluting polymer (Evermine 50) in real-world patients with coronary artery disease.</p><p><strong>Methods: </strong>A single-arm, multicenter, prospective study was conducted in real-world patients. A total of 161 patients with de novo lesions who received at least 1 UTS stent were enrolled. The primary safety endpoint was the occurrence of major adverse cardiovascular events, defined as cardiac death, target-vessel myocardial infarction, or the need for revascularization of the target lesion at 12 months. The incidence of stent thrombosis at 12 months was also analyzed.</p><p><strong>Results: </strong>The study included 161 patients with a mean age of 64 ± 14 years; 79% were male, 34% had diabetes, and 66% had hypertension. The most common indication for intervention was non-ST-segment elevation myocardial infarction (42%), followed by ST-segment elevation myocardial infarction (22%). The procedural success rate was 100%. At 12 months of follow-up, the incidence of MACE was 2.5%, and the definite stent thrombosis rate was 1.3%.</p><p><strong>Conclusions: </strong>The use of the 50 µm UTS stent with a biodegradable everolimus-eluting polymer demonstrated a favorable safety profile and good clinical outcomes in unselected patients at 1 year of follow-up.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"7 1","pages":"23-28"},"PeriodicalIF":1.2000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097315/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"REC Interventional Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/RECIC.M24000484","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and objectives: Ultrathin-strut stents (UTS) represent a significant advancement in percutaneous coronary intervention. This study aimed to evaluate the safety and short- to mid-term outcomes of stenting with the thinnest struts on the market (50 µm) using a biodegradable everolimus-eluting polymer (Evermine 50) in real-world patients with coronary artery disease.
Methods: A single-arm, multicenter, prospective study was conducted in real-world patients. A total of 161 patients with de novo lesions who received at least 1 UTS stent were enrolled. The primary safety endpoint was the occurrence of major adverse cardiovascular events, defined as cardiac death, target-vessel myocardial infarction, or the need for revascularization of the target lesion at 12 months. The incidence of stent thrombosis at 12 months was also analyzed.
Results: The study included 161 patients with a mean age of 64 ± 14 years; 79% were male, 34% had diabetes, and 66% had hypertension. The most common indication for intervention was non-ST-segment elevation myocardial infarction (42%), followed by ST-segment elevation myocardial infarction (22%). The procedural success rate was 100%. At 12 months of follow-up, the incidence of MACE was 2.5%, and the definite stent thrombosis rate was 1.3%.
Conclusions: The use of the 50 µm UTS stent with a biodegradable everolimus-eluting polymer demonstrated a favorable safety profile and good clinical outcomes in unselected patients at 1 year of follow-up.